Contraception
Volume 81, Issue 6 , Pages 487-495 , June 2010

Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously

  • Penina Segall-Gutierrez

      Affiliations

    • Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    • Corresponding Author InformationCorresponding author. LAC+USC Medical Center, Los Angeles, CA 90033, USA. Tel.: +1 323 226 5408; fax: +1 323 226 3424.
    • ,
  • DeShawn Taylor

      Affiliations

    • Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    • ,
  • Xinwen Liu

      Affiliations

    • Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    • ,
  • Frank Stanzcyk

      Affiliations

    • Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    • ,
  • Stanley Azen

      Affiliations

    • Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    • ,
  • Daniel R. Mishell Jr

      Affiliations

    • Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

Received 12 August 2009 ,Revised 8 December 2009 ,Accepted 26 January 2010.

References 

  1. Mishell DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41:381–390
  2. Trussell J. Contraeptive failure in the United States. Contraception. 2004;70:89–96
  3. World Health Organization (WHO) . Medical eligibility criteria for contraceptive use 2008 update. http://www.whqlibdoc.who.int/hq/2008/WHO_RHR_08.19_eng.pdf
  4. Center for Disease Control (CDC) . U.S. obesity trends 1985-2008. http://www.cdc.gov/nccdphp/dnpa/obesity/trend.htmlAccessed online July 8, 2009
  5. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States 1999-2004. JAMA. 2006;295:1549–1555
  6. Siega-Riz AM, Laraia B. The implications of maternal overweight and obesity on the course of pregnancy and birth outcomes. Matern Child Health J. 2006;10:S153–S156
  7. Ortiz A, Hiroi M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44:32–38
  8. Fotherby K, Koetsawang S. Metabolism of injectable formulations of contraception in obese and thin Thai women. Contraception. 1982;26:51–58
  9. Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E. Return of ovulation following a single injection of depo-medroxyprogesterone acetate. Contraception. 1984;29:1–18
  10. Smit J, Botha J, McFadyen L, Beksinska M. Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of dosing interval. Contraception. 2004;69:3–7
  11. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70:269–275
  12. Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR. Pharmacokinetics, ovulation suppression, and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception. 2004;70:11–18
  13. Hiroi M, Stanczyk FZ, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DR, et al. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids. 1975;26:373–386
  14. Jeppsson S, Johansson EDB, Sjöberg NO. Plasma levels of estrogens during long-term treatment with depo-medroxyprogesterone acetate as a contraceptive agent. Contraception. 1973;8:165–170
  15. Mishell DR, Kharma KM, Thorneycroft IH, Nakamura RM. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol. 1972;113:372–376
  16. Nelson AL, Katz T. Initiation and continuation rates seen in 2-year experience with same day injections of DMPA. Contraception. 2007;75:84–87
  17. The Center for Reproductive Health Education in Family Medicine (RHEDI) Quick Start Algorithm. http://www.rhedi.org/contraception/quick_start_algorithm.phpAccessed online July 9, 2009
  18. Watkins T. Reproductive Health Advisory Committee meeting minutes from January 23-24, 2007. http://www.fda.gov/ohrms/dockets/ac/cder07.htm#rhdacAccessed online July 9, 2009
  19. Segall-Gutierrez P, Zhing L, Mishell DR. DMPA use in obese and morbidly obese women: incidence of ovulation. Contraception. 2007;76:171
  20. Segall-Gutierrez P, Taylor D, Azen S. Increased incidence of follicular development in obese women using subcutaneous depomedroxyprogesterone acetate (DMPA-SC) Contraception. Obesity. 2008;16(Suppl):S1–S162

PII: S0010-7824(10)00041-7

doi: 10.1016/j.contraception.2010.01.021

Contraception
Volume 81, Issue 6 , Pages 487-495 , June 2010

Article Tools

* Image Usage & Resolution